Trial Profile
Pharmacoepidemiology Study to Define the Long-term Safety Profile of Tenofovir Disoproxil Fumarate (Tenofovir DF, Viread) and Describe the Management of Tenofovir DF-associated Renal and Bone Toxicity in Chronic Hepatitis B (CHB)-Infected Adolescents Aged 12 to <18 Years in Europe
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 13 Aug 2021
Price :
$35
*
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 21 Feb 2019 Status changed from completed to discontinued.
- 19 Apr 2018 Status changed from active, no longer recruiting to completed.
- 06 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.